Hydralazine/isosorbide dinitrate,
does it really help with Reduced all-cause mortality and heart-failure hospitalization in Black patients with severe HFrEF receiving standard therapy?
research showsFixed-dose hydralazine/isosorbide dinitrate is rated A because it reduces all-cause mortality and first heart-failure hospitalization in Black patients with severe HFrEF receiving standard therapy. A-HeFT randomized 1,050 participants to placebo or the fixed combination and stopped early after mortality was 6.2% versus 10.2%, a 43% relative reduction with hazard ratio 0.57. First heart-failure hospitalization was 16.4% versus 22.4%, a 33% relative reduction. Although it is one trial in a specific population, a sufficiently large placebo-controlled, drug-specific mortality endpoint supports A.
ads claimCalling it an essential mortality drug for every patient with heart failure exceeds the evidence. The direct A evidence concerns symptomatic severe HFrEF in Black patients despite standard therapy, and it does not replace foundational ARNI, beta-blocker, MRA, or SGLT2-inhibitor treatment.
Useful facts when choosing a product
- Each BiDil tablet contains isosorbide dinitrate 20 mg and hydralazine hydrochloride 37.5 mg; prescription dosing is generally titrated from a lower dose toward three-times-daily administration.
- It is added to standard HFrEF therapy and should not be used to replace or stop foundational guideline-directed treatment without clinical direction.
- Headache, dizziness, tachycardia, hypotension, and nausea are common, and hydralazine can cause a lupus-like syndrome.
- Combining a nitrate with a PDE5 inhibitor or riociguat can cause severe hypotension and is contraindicated; this fixed heart-failure combination is distinct from nitroglycerin for angina.
What the research actually shows
Taylor and colleagues randomized 1,050 Black patients with NYHA class III to IV heart failure to fixed-dose isosorbide dinitrate/hydralazine or placebo in addition to standard therapy. All-cause mortality was 6.2% versus 10.2% (HR 0.57), and first heart-failure hospitalization was 16.4% versus 22.4%; the trial stopped early for the mortality difference. The 2022 AHA/ACC/HFSA guideline recommends this combination to improve symptoms and reduce morbidity and mortality in self-identified Black patients with NYHA class III to IV HFrEF receiving optimal therapy.
Why this is classified as A (88)
A-HeFT was a 1,050-participant placebo-controlled randomized trial showing all-cause mortality HR 0.57 and a 33% relative reduction in first heart-failure hospitalization attributable to the fixed combination. Although limited to Black patients with severe HFrEF, the large randomized hard mortality endpoint meets the exception for A with 88 points. Hypotension and lupus-like reactions are separate safety issues.
Counterpoint. Use should match the directly studied and guideline population: self-identified Black patients with NYHA class III to IV HFrEF receiving optimized foundational therapy.
Rejudgment record. New verdict — Centered the assessment on the drug-specific placebo-controlled all-cause mortality and first heart-failure hospitalization endpoints in A-HeFT, explicitly retaining the Black NYHA class III to IV HFrEF scope while applying the large-RCT mortality exception for A
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced all-cause mortality | A | A-HeFT found 6.2% versus 10.2%, HR 0.57, a 43% relative reduction. |
| Reduced first heart-failure hospitalization | A | It fell from 22.4% to 16.4%, a 33% relative reduction. |
| Improved quality of life | B | The quality-of-life component of the A-HeFT composite also improved versus placebo. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Taylor AL et al. 2004 A-HeFT | Multicenter randomized double-blind placebo-controlled trial | 1,050 | NitroMed and academic investigators | All-cause death, first heart-failure hospitalization, and quality-of-life composite | Mortality 6.2% versus 10.2%, HR 0.57; first hospitalization 16.4% versus 22.4%, a 33% relative reduction. | Drug-specific large hard mortality endpoint |
| Heidenreich PA et al. 2022 AHA/ACC/HFSA guideline | Systematic evidence review and clinical practice guideline | AHA, ACC, and HFSA | Symptoms, morbidity, and mortality | Recommends the combination in self-identified Black patients with NYHA class III to IV HFrEF receiving optimal therapy. | Applicability and standard-treatment context |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-23).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-23 · Corrections: none
Cite this verdict
[Chamgap] Hydralazine/isosorbide dinitrate x lower mortality and hospitalization in Black patients with severe HFrEF — Evidence Grade A·88. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/hydralazine-isosorbide-dinitrate-black-hfref-mortality-hospitalization/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.